Finance

Lists
MAZE:NASDAQ
Maze Therapeutics Inc
26,43 US$
-0,83%
(-0,22) 1D
2 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MAZE...
Open
27,08 US$
High
27,49 US$
Low
26,36 US$
Mkt. cap
1,47 მლრდ.
Avg. vol.
702,40 ათ.
Volume
0,00
52-wk high
53,65 US$
52-wk low
21,95 US$
EPS
-2,51 US$
Shares outstanding
55,55 მლნ.
No. of employees
141
Open
27,08 US$
High
27,49 US$
Low
26,36 US$
Mkt. cap
1,47 მლრდ.
Avg. vol.
702,40 ათ.
Volume
0,00
52-wk high
53,65 US$
52-wk low
21,95 US$
EPS
-2,51 US$
Shares outstanding
55,55 მლნ.
No. of employees
141
News stories
From web sources and news partners
About Maze Therapeutics Inc
CEO-
Employees141
Founded2017
HeadquartersSouth San Francisco, კალიფორნია, ამერიკის შეერთებული შტატები
SectorPharmaceutical industry
Websitemazetx.com
Analyst ratings
Based on 7 analysts giving stock ratings to MAZE in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for MAZE in the last 3 months.
Highest
Current 26,43 US$
110,00 US$ (+316,19%)
Average
61,43 US$ (+132,43%)
Lowest
46,00 US$ (+74,04%)
Analyst
Recommendation
Action
Price target
Projected
Date
Laura Chico
Wedbush
Buy
Maintained
48,00 US$
+81,6%
09/23/2026
Julian Harrison
BTIG
Buy
Maintained
46,00 US$
+74%
09/22/2026
Eric Joseph
Citi
Buy
Initiated
50,00 US$
+89,2%
09/23/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
57,00 US$
+115,7%
09/22/2026
Ananda Ghosh
H.C. Wainwright
Buy
Maintained
110,00 US$
+316,2%
09/22/2026
Danielle Brill
Truist Financial
Buy
Maintained
64,00 US$
+142,1%
09/22/2026
Sadia Rahman
Wells Fargo
Buy
Maintained
55,00 US$
+108,1%
09/09/2026
Salim Syed
Mizuho Securities
Buy
Maintained
97,00 US$
+267%
06/23/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
53,00 US$
+100,5%
05/22/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/12/2026
Martin Auster
Raymond James
Buy
Reiterated
56,00 US$
+111,9%
03/25/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
50,00 US$
+89,2%
03/25/2026
Debjit Chattopadhyay
Guggenheim
Buy
Reiterated
58,00 US$
+119,4%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
20,00 მლნ.
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
25,19 მლნ.
27,57 მლნ.
34,15 მლნ.
34,94 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,78 მლნ.
10,49 მლნ.
12,40 მლნ.
13,10 მლნ.
Operating expense
32,96 მლნ.
38,06 მლნ.
46,55 მლნ.
48,04 მლნ.
Total operating expenses
32,96 მლნ.
38,06 მლნ.
46,55 მლნ.
48,04 მლნ.
Operating income
-32,96 მლნ.
-38,06 მლნ.
-26,55 მლნ.
-48,04 მლნ.
Other non operating income
-
-
-
-
EBT including unusual items
-30,09 მლნ.
-34,57 მლნ.
-24,21 მლნ.
-44,73 მლნ.
EBT excluding unusual items
-30,09 მლნ.
-34,57 მლნ.
-24,21 მლნ.
-44,73 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-30,09 მლნ.
-34,57 მლნ.
-24,21 მლნ.
-44,73 მლნ.
Net profit margin
-
-
-121,04%
-
Earnings per share
-0,66
-0,65
-0,45
-0,76
Interest and investment income
2,88 მლნ.
3,49 მლნ.
3,21 მლნ.
4,24 მლნ.
Interest expense
-
-
-866,00 ათ.
-931,00 ათ.
Net interest expenses
2,88 მლნ.
3,49 მლნ.
2,34 მლნ.
3,31 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-32,39 მლნ.
-37,56 მლნ.
-26,11 მლნ.
-47,64 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები